Illustris is a clinical-stage biodevelopment company whose objective is to reduce society’s exposure to potentially harmful active agents by utilizing our novel permeation technology to deliver active agents through tissue structures more efficiently. Our strategy is to manufacture and license our permeation technology while developing our own pharmaceutical products for commercial sale upon regulatory approval. The Illustris technology platform ("ITP") both enables the delivery of large molecules (of at least 500KD) through tissue structures, and optimizes the absorption of compounds typically delivered through skin, eyes and mucosal (oral or vaginal) surfaces and also has agricultural applications. The ITP facilitates the delivery of active agents through tissue structures by deploying “decoys”, many of which temporarily distract and relax anchors that bind tissue cells together, providing a portal for active agents to permeate the targeted site. Based on the clinical objective, Illustris can deploy the appropriate amount of decoy to fully penetrate or partially permeate the targeted tissue structure or organ system. The Illustris proprietary family of technologies enables the delivery through tissue structures of macromolecule active ingredients (of at least 500KD) which are historically difficult or impossible to deliver topically, and optimizes delivery of active agents which previously permeated tissue structures inefficiently. Illustris has filed broad patent applications across several classes of applications and compounds. We believe upon the conclusion of the appropriate studies, the Illustris family of technologies will provide a significant competitive advantage with its novel approach to molecule delivery yielding enhanced safety and efficacy for patients.